Navigation Links
Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
Date:2/11/2008

Results reported in The Journal of Immunology

SEATTLE, Feb. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced that pixantrone was shown to reduce the severity of clinical manifestation in the animal model of the autoimmune disease myasthenia gravis (MG). MG is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal (voluntary) muscles of the body due to autoantibodies acting against the Acethylcholine Receptor. The preclinical study was published in The Journal of Immunology (180:2696-2703, 2008) by Fulvio Baggi, M.D. and Renato Mantegazza, M.D., of the "Carlo Besta" Neurological Institute Foundation in Milan. The study compared pixantrone with the related drug, mitoxantrone, an agent currently approved to treat severe multiple sclerosis, also an autoimmune disease that attacks the central nervous system. In the current study, pixantrone was found to be more effective than mitoxantrone at improving both the laboratory and the clinical manifestations of the MG equivalent in rats. The authors concluded that "pixantrone [is] a promising immunosuppressant agent suitable for clinical investigation in myasthenia gravis, although additional experiments are needed to confirm its safety profile in prolonged treatments."

Current therapeutic treatment options for myasthenia gravis include corticosteroids and immunosuppressive drugs, both of which are effective in most patients. However, some patients do not respond to the standard treatments, and side effects may limit prolonged administration. Mitoxantrone has a broad immunosuppressive effect, but has cumulative cardiotoxicity and prolonged treatment can result in a decrease in left ventricular ejection fraction (LVEF -- the amount of blood the heart pumps out with each beat) or, rarely, congestive heart failure. Pixantrone's mechanism of action is similar to that of mitoxantrone -- both act as DNA interc
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
2. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
3. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
4. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
5. Newly Approved HIV Drug Shows Great Promise
6. Kaiser Permanente - Group Health Study Shows Depression Worsens HIV Treatment
7. Research Shows Decas Sweetened Dried Cranberries Pack Twice the Proanthocyanidin Punch as Cranberry Juice Cocktail
8. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
9. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
10. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
11. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...utomation and intelligent clinical applications ta... level , , CHICAGO, Ill., Nov. 26 /PRNewswi...ens.com/healthcare ) highlights the ACUSON S2000(...e world,s first multi-use, automated volume breast...y and Annual Meeting of the Radiological Society o...
(Date:11/25/2008)...against expanding statin use broadly in wake of AH...ov. 25 JUPITER, a clinical trial s...r risk of healthy patients with elevated CRP, shou..., according to a national poll directed at health ...n the online poll conducted by medical news site M...
(Date:11/25/2008)...l Trial to Assess Survival of Patients Receiving L...able Hepatocellular Carcinoma , , BELLEVUE,...ology, Inc. (LSO) today announced the completion o... Light Infusion Therapy(TM) (Litx(TM)) as a treatm...), also known as hepatoma or primary liver cancer....
(Date:11/24/2008)...swire-FirstCall/ -- Leaders of Schering-Plough Cor...or investors on the company,s research pipeline, h...ncludes 46 new entities in clinical trials or unde... , , "Research and development is adding st...ue our transformation," said Fred Hassan, chairman...
Breaking Medicine Technology:Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5ViroPharma Receives European Orphan Drug Designation for CAMVIA 28TM 29 6092 1ViroPharma Receives European Orphan Drug Designation for CAMVIA 28TM 29 6092 2ViroPharma Receives European Orphan Drug Designation for CAMVIA 28TM 29 6092 3ViroPharma Receives European Orphan Drug Designation for CAMVIA 28TM 29 6092 4American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 6090 1American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 6090 2Researchers identify how to switch off cancer cell genes 1186 1Earth Observation essential for geohazard mitigation 1184 1Earth Observation essential for geohazard mitigation 1184 2Earth Observation essential for geohazard mitigation 1184 3
...n,s pipeline provide support for,epigenetic and co...,data on use of Thalidomide to treat multiple myel...tCall/ -- Pharmion,Corporation reported today that...he company,s marketed and pipeline products will b...f Clinical,Oncology,s (ASCO) 43rd Annual Meeting i...
...2007 - Introgen Therapeutics, Inc.,(NASDAQ:INGN) r...N,241, the Company,s novel investigational mda-7/I...nced solid tumors., The data (Abstract #380), whic...e American Society of Gene Therapy, showed that,in...n all treated,tumors, including in those patients ...
Other Medicine Technology:Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 2Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 3Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 4Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 5Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 6Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 7Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 2Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 3
(Date:12/1/2008)...news event -- Hall of States, Room 333 -- 444 Nort..., WASHINGTON, Dec. 1 ...oming together to outline the current fiscal situa...ext Administration to provide a recovery package t...rojects and ease the burden of Medicaid costs. As ...
(Date:12/1/2008)...wire/ -- An independent study at the,University o...want to play,video games at the same time as exer... , Fifty children aged 11 and 12 were asked...mes provided by a company called Gamercize. , ...they maintained movement on,the fitness machines....
(Date:12/1/2008)...Newswire/ -- Transcept Pharmaceuticals,Inc., a p...nounced today that,Glenn A. Oclassen, President &...ticipate at the RBC Capital Markets 2008 Healthcar... "Delivering Novel Drug Solutions: The Future of D... take place on Thursday, December,11, 2008 at 1:3...
(Date:12/1/2008)... Cardinal,Health and SR...ar supply and,co-marketing agreement to offer sur...oducts from Cardinal Health and reusable health ca...ment makes Cardinal Health the exclusive manufactu...400 disposable surgical kits. In,addition, the ag...
Breaking Medicine News(10 mins):Health News:Governors, Legislators Update Current State Fiscal Conditions, Push for Economic Recovery Package from Congress, President-elect 2Health News:Children Tell Researchers: We'll Get Fit if It's Fun 2Health News:Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel 2Health News:Cardinal Health, SRI Surgical Sign Five-Year Agreement For Surgical Kits 2Health News:Cardinal Health, SRI Surgical Sign Five-Year Agreement For Surgical Kits 3
...hKline (GSK) has reached an agreement with Eliot S... that it deceptively tried to delay competitors fr...-depressant drug Paxil.// GSK was allegedly inv... generic producers of Paxil in a bind of using fri...
...abani and his assistant Kartar Singh have been sen...of a fetus and then agreeing to abort it if it was... practitioner has been jailed for carrying out ill...ions. The perpetrators were found out when govern...
...onfections, Inc. of Dallas, Texas are tough nuts t...batch of production of Sam's Choice Belgian Milk C... almonds. This is a precautionary measure to ensur...ic to almonds that may cause a life threatening re...
... testing for HIV/AIDS in countries with high infec...er US president. // There was a stigma attached ...r those infected few decades ago and so AIDS testi... to Clinton, countries where there was no discrimi...
Other Medicine News:
The challenge for Carl Zeiss was to find innovative solutions for measurements on the eye and for preoperative computation of intraocular lenses (IOL). The result of this development work is the IOLM
Ahmed Glaucoma Valve (small size) with Pars Plana Clip .
Ahmed Glaucoma Valve.
...ompatibility is established. Provides a robust and...nsure correct positioning on the globe. Pressure R...h, when covered by Tenons tissue, acts as a Pressu...ive hypotony. The range of implants allows the sur...
Medicine Products: